|
|
Volumn 8, Issue 17, 2003, Pages 775-777
|
|
Paul Workman on the challenges of cancer drug development
|
|
Author keywords
Apoptosis; Cancer; Cancer biology; Cyclin dependent kinases; Drug Discovery; Gleevec; Histone deacetylase; Pharmaceutical Science; Pharmacology
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CARBOPLATIN;
CYCLIN DEPENDENT KINASE INHIBITOR;
GEFITINIB;
IMATINIB;
PROTEIN TYROSINE KINASE;
RALTITREXED;
ROSCOVITINE;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
CYTOTOXICITY;
DEREGULATION;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUG SYNTHESIS;
DRUG TARGETING;
EXPERIENCE;
HUMAN;
LUNG NON SMALL CELL CANCER;
MOLECULAR DYNAMICS;
PROTEIN EXPRESSION;
REVIEW;
|
|
EID: 0041932074
PISSN: 13596446
EISSN: None
Source Type: Journal
DOI: 10.1016/S1359-6446(03)02838-1 Document Type: Note |
|
Times cited : (6)
|
|
References (0)
|
